VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q114067347 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241120235950.0
008 241120nneanz||abbn n and d
035 ‎‡a (WKP)Q114067347‏
035 ‎‡a (OCoLC)Q114067347‏
100 0 ‎‡a B. Delia Johnson‏ ‎‡c epidemiologist‏ ‎‡9 en‏
375 ‎‡a 2‏ ‎‡2 iso5218‏
670 ‎‡a Author's Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE).‏
670 ‎‡a Author's Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation‏
670 ‎‡a Author's ANGINA AND ANTI-ANGINAL THERAPY IN WOMEN WITH SIGNS AND SYMPTOMS OF ISCHEMIA AND NO OBSTRUCTIVE CORONARY ARTERY DISEASE‏
670 ‎‡a Author's Angina Hospitalization Rates in Women With Signs and Symptoms of Ischemia But no Obstructive Coronary Artery Disease: A Report from the WISE (Women's Ischemia Syndrome Evaluation) Study‏
670 ‎‡a Author's Anxiety associations with cardiac symptoms, angiographic disease severity, and healthcare utilization: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation‏
670 ‎‡a Author's Associations Among Walking Performance, Physical Activity, and Subclinical Cardiovascular Disease‏
670 ‎‡a Author's Bio-informatics assessment schema‏
670 ‎‡a Author's Bio-informatics assessment schema (BIAS) to improve myocardial perfusion image diagnostic and prognostic value: the NHLBI-sponsored women's ischemia syndrome evaluation (WISE) study.‏
670 ‎‡a Author's Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction. A National Heart, Lung, and Blood Institute-sponsored study from the Women's Ischemia Syndrome Evaluation.‏
670 ‎‡a Author's Carotid artery distensibility and hormone therapy and menopause: the Los Angeles Atherosclerosis Study‏
670 ‎‡a Author's Clinical implications of the Women's Ischemia Syndrome Evaluation: inter-relationships between symptoms, psychosocial factors and cardiovascular outcomes‏
670 ‎‡a Author's Combining psychosocial data to improve prediction of cardiovascular disease risk factors and events: The National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation study‏
670 ‎‡a Author's Comparison of low and high dose intracoronary adenosine and acetylcholine in women undergoing coronary reactivity testing: results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation‏
670 ‎‡a Author's Comparison of low and high dose intracoronary adenosine and acetylcholine in women undergoing coronary reactivity testing: results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE).‏
670 ‎‡a Author's DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health--National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE)‏
670 ‎‡a Author's Diabetes mellitus, hypothalamic hypoestrogenemia, and coronary artery disease in premenopausal women (from the National Heart, Lung, and Blood Institute sponsored WISE study).‏
670 ‎‡a Author's Importance of socioeconomic status as a predictor of cardiovascular outcome and costs of care in women with suspected myocardial ischemia. Results from the National Institutes of Health, National Heart, Lung and Blood Institute-sponsored Women's Isc‏
670 ‎‡a Author's In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the Nation‏
670 ‎‡a Author's Increased wave reflection and ejection duration in women with chest pain and nonobstructive coronary artery disease: ancillary study from the Women's Ischemia Syndrome Evaluation.‏
670 ‎‡a Author's Inflammatory biomarkers as predictors of heart failure in women without obstructive coronary artery disease: A report from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE).‏
670 ‎‡a Author's Left Ventricular Energy Model Predicts Adverse Events in Women With Suspected Myocardial Ischemia: Results From The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation‏
670 ‎‡a Author's Left Ventricular Energy Model Predicts Adverse Events in Women With Suspected Myocardial Ischemia: Results From The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study‏
670 ‎‡a Author's MICROVASCULAR CORONARY DYSFUNCTION, LEFT VENTRICULAR VOLUMES AND MASS: RESULTS FROM THE WOMEN'S ISCHEMIA SYNDROME EVALUATION-CORONARY VASCULAR DYSFUNCTION STUDY‏
670 ‎‡a Author's Mild renal dysfunction and long-term adverse outcomes in women with chest pain: results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE)‏
670 ‎‡a Author's Multimarker approach predicts adverse cardiovascular events in women evaluated for suspected ischemia: results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation‏
670 ‎‡a Author's Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation‏
670 ‎‡a Author's Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute spons‏
670 ‎‡a Author's Premature atherosclerosis in premenopausal women: Does cytokine balance play a role?‏
670 ‎‡a Author's Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE).‏
670 ‎‡a Author's Prognostic value of global MR myocardial perfusion imaging in women with suspected myocardial ischemia and no obstructive coronary disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study‏
670 ‎‡a Author's Pulse pressure and adverse outcomes in women: a report from the Women's Ischemia Syndrome Evaluation (WISE)‏
670 ‎‡a Author's Relations between endogenous androgens and estrogens in postmenopausal women with suspected ischemic heart disease‏
670 ‎‡a Author's Relationships between cardiovascular disease risk factors and depressive symptoms as predictors of cardiovascular disease events in women‏
670 ‎‡a Author's Renal function and coronary microvascular dysfunction in women with symptoms/signs of ischemia‏
670 ‎‡a Author's Reproductive hormone exposure timing and ischemic heart disease: Complicated answers to a simple question‏
670 ‎‡a Author's Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE‏
670 ‎‡a Author's Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study‏
670 ‎‡a Author's Self-rated versus objective health indicators as predictors of major cardiovascular events: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation.‏
670 ‎‡a Author's SENSITIVITY AND SPECIFICITY OF CMRI FOR DIAGNOSIS OF MICROVASCULAR CORONARY DYSFUNCTION IN WOMEN WITH SIGNS AND SYMPTOMS OF ISCHEMIA AND NO OBSTRUCTIVE CORONARY ARTERY DISEASE: RESULTS FROM THE NHLBI-SPONSORED WOMEN'S ISCHEMIA SYNDROME EVALUATION‏
670 ‎‡a Author's SENSITIVITY AND SPECIFICITY OF CMRI FOR DIAGNOSIS OF MICROVASCULAR CORONARY DYSFUNCTION IN WOMEN WITH SIGNS AND SYMPTOMS OF ISCHEMIA AND NO OBSTRUCTIVE CORONARY ARTERY DISEASE: RESULTS FROM THE NHLBI-SPONSORED WOMEN'S ISCHEMIA SYNDROME EVALUATION (WI‏
670 ‎‡a Author's The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation‏
670 ‎‡a Author's The relationship between physical activity and lipoprotein subclasses in postmenopausal women‏
670 ‎‡a Author's TIMI frame count and adverse events in women with no obstructive coronary disease: a pilot study from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation‏
670 ‎‡a Author's TIMI frame count and adverse events in women with no obstructive coronary disease: a pilot study from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE)‏
670 ‎‡a Author's Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation.‏
919 ‎‡a associationsamongwalkingperformancephysicalactivityandsubclinicalcardiovasculardisease‏ ‎‡A Associations Among Walking Performance, Physical Activity, and Subclinical Cardiovascular Disease‏ ‎‡9 1‏
919 ‎‡a anxietyassociationswithcardiacsymptomsangiographicdiseaseseverityandhealthcareutilizationthenhlbisponsoredwomensischemiasyndromeevaluation‏ ‎‡A Anxiety associations with cardiac symptoms, angiographic disease severity, and healthcare utilization: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation‏ ‎‡9 1‏
919 ‎‡a anginahospitalizationratesinwomenwithsignsandsymptomsofischemiabutnoobstructivecoronaryarterydiseaseareportfromthewisewomensischemiasyndromeevaluationstudy‏ ‎‡A Angina Hospitalization Rates in Women With Signs and Symptoms of Ischemia But no Obstructive Coronary Artery Disease: A Report from the WISE (Women's Ischemia Syndrome Evaluation) Study‏ ‎‡9 1‏
919 ‎‡a anginaandantianginaltherapyinwomenwithsignsandsymptomsofischemiaandnoobstructivecoronaryarterydisease‏ ‎‡A ANGINA AND ANTI-ANGINAL THERAPY IN WOMEN WITH SIGNS AND SYMPTOMS OF ISCHEMIA AND NO OBSTRUCTIVE CORONARY ARTERY DISEASE‏ ‎‡9 1‏
919 ‎‡a adrenergicgenepolymorphismsandcardiovascularriskinthenhlbisponsoredwomensischemiasyndromeevaluation‏ ‎‡A Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women's Ischemia Syndrome Evaluation‏ ‎‡9 1‏
919 ‎‡a abnormalcoronaryvasomotionasaprognosticindicatorofcardiovasculareventsinwomenresultsfromthenationalheartlungandbloodinstitutesponsoredwomensischemiasyndromeevaluationwise‏ ‎‡A Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE).‏ ‎‡9 1‏
919 ‎‡a cardiacmagneticresonancemyocardialperfusionreserveindexisreducedinwomenwithcoronarymicrovasculardysfunctionanationalheartlungandbloodinstitutesponsoredstudyfromthewomensischemiasyndromeevaluation‏ ‎‡A Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction. A National Heart, Lung, and Blood Institute-sponsored study from the Women's Ischemia Syndrome Evaluation.‏ ‎‡9 1‏
919 ‎‡a carotidarterydistensibilityandhormonetherapyandmenopausethelosangelesatherosclerosisstudy‏ ‎‡A Carotid artery distensibility and hormone therapy and menopause: the Los Angeles Atherosclerosis Study‏ ‎‡9 1‏
919 ‎‡a clinicalimplicationsofthewomensischemiasyndromeevaluationinterrelationshipsbetweensymptomspsychosocialfactorsandcardiovascularoutcomes‏ ‎‡A Clinical implications of the Women's Ischemia Syndrome Evaluation: inter-relationships between symptoms, psychosocial factors and cardiovascular outcomes‏ ‎‡9 1‏
919 ‎‡a combiningpsychosocialdatatoimprovepredictionofcardiovasculardiseaseriskfactorsandeventsthenationalheartlungandbloodinstitutesponsoredwomensischemiasyndromeevaluationstudy‏ ‎‡A Combining psychosocial data to improve prediction of cardiovascular disease risk factors and events: The National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation study‏ ‎‡9 1‏
919 ‎‡a comparisonoflowandhighdoseintracoronaryadenosineandacetylcholineinwomenundergoingcoronaryreactivitytestingresultsfromthenhlbisponsoredwomensischemiasyndromeevaluation‏ ‎‡A Comparison of low and high dose intracoronary adenosine and acetylcholine in women undergoing coronary reactivity testing: results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation‏ ‎‡9 1‏
919 ‎‡a comparisonoflowandhighdoseintracoronaryadenosineandacetylcholineinwomenundergoingcoronaryreactivitytestingresultsfromthenhlbisponsoredwomensischemiasyndromeevaluationwise‏ ‎‡A Comparison of low and high dose intracoronary adenosine and acetylcholine in women undergoing coronary reactivity testing: results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE).‏ ‎‡9 1‏
919 ‎‡a dheaslevelsandcardiovasculardiseasemortalityinpostmenopausalwomenresultsfromthenationalinstitutesofhealthnationalheartlungandbloodinstitutenhlbisponsoredwomensischemiasyndromeevaluationwise‏ ‎‡A DHEA-S levels and cardiovascular disease mortality in postmenopausal women: results from the National Institutes of Health--National Heart, Lung, and Blood Institute (NHLBI)-sponsored Women's Ischemia Syndrome Evaluation (WISE)‏ ‎‡9 1‏
919 ‎‡a diabetesmellitushypothalamichypoestrogenemiaandcoronaryarterydiseaseinpremenopausalwomenfromthenationalheartlungandbloodinstitutesponsoredwisestudy‏ ‎‡A Diabetes mellitus, hypothalamic hypoestrogenemia, and coronary artery disease in premenopausal women (from the National Heart, Lung, and Blood Institute sponsored WISE study).‏ ‎‡9 1‏
919 ‎‡a importanceofsocioeconomicstatusasapredictorofcardiovascularoutcomeandcostsofcareinwomenwithsuspectedmyocardialischemiaresultsfromthenationalinstitutesofhealthnationalheartlungandbloodinstitutesponsoredwomensisc‏ ‎‡A Importance of socioeconomic status as a predictor of cardiovascular outcome and costs of care in women with suspected myocardial ischemia. Results from the National Institutes of Health, National Heart, Lung and Blood Institute-sponsored Women's Isc‏ ‎‡9 1‏
919 ‎‡a inwomenwithsymptomsofcardiacischemianonobstructivecoronaryarteriesandmicrovasculardysfunctionangiotensinconvertingenzymeinhibitionisassociatedwithimprovedmicrovascularfunctionadoubleblindrandomizedstudyfromthenation‏ ‎‡A In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the Nation‏ ‎‡9 1‏
919 ‎‡a increasedwavereflectionandejectiondurationinwomenwithchestpainandnonobstructivecoronaryarterydiseaseancillarystudyfromthewomensischemiasyndromeevaluation‏ ‎‡A Increased wave reflection and ejection duration in women with chest pain and nonobstructive coronary artery disease: ancillary study from the Women's Ischemia Syndrome Evaluation.‏ ‎‡9 1‏
919 ‎‡a inflammatorybiomarkersaspredictorsofheartfailureinwomenwithoutobstructivecoronaryarterydiseaseareportfromthenhlbisponsoredwomensischemiasyndromeevaluationwise‏ ‎‡A Inflammatory biomarkers as predictors of heart failure in women without obstructive coronary artery disease: A report from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE).‏ ‎‡9 1‏
919 ‎‡a leftventricularenergymodelpredictsadverseeventsinwomenwithsuspectedmyocardialischemiaresultsfromthenhlbisponsoredwomensischemiasyndromeevaluation‏ ‎‡A Left Ventricular Energy Model Predicts Adverse Events in Women With Suspected Myocardial Ischemia: Results From The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation‏ ‎‡9 1‏
919 ‎‡a leftventricularenergymodelpredictsadverseeventsinwomenwithsuspectedmyocardialischemiaresultsfromthenhlbisponsoredwomensischemiasyndromeevaluationwisestudy‏ ‎‡A Left Ventricular Energy Model Predicts Adverse Events in Women With Suspected Myocardial Ischemia: Results From The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study‏ ‎‡9 1‏
919 ‎‡a microvascularcoronarydysfunctionleftventricularvolumesandmassresultsfromthewomensischemiasyndromeevaluationcoronaryvasculardysfunctionstudy‏ ‎‡A MICROVASCULAR CORONARY DYSFUNCTION, LEFT VENTRICULAR VOLUMES AND MASS: RESULTS FROM THE WOMEN'S ISCHEMIA SYNDROME EVALUATION-CORONARY VASCULAR DYSFUNCTION STUDY‏ ‎‡9 1‏
919 ‎‡a mildrenaldysfunctionandlongtermadverseoutcomesinwomenwithchestpainresultsfromthenationalheartlungandbloodinstitutesponsoredwomensischemiasyndromeevaluationwise‏ ‎‡A Mild renal dysfunction and long-term adverse outcomes in women with chest pain: results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE)‏ ‎‡9 1‏
919 ‎‡a multimarkerapproachpredictsadversecardiovasculareventsinwomenevaluatedforsuspectedischemiaresultsfromthenationalheartlungandbloodinstitutesponsoredwomensischemiasyndromeevaluation‏ ‎‡A Multimarker approach predicts adverse cardiovascular events in women evaluated for suspected ischemia: results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation‏ ‎‡9 1‏
919 ‎‡a pastoralcontraceptiveuseandangiographiccoronaryarterydiseaseinpostmenopausalwomendatafromthenationalheartlungandbloodinstitutesponsoredwomensischemiasyndromeevaluation‏ ‎‡A Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation‏ ‎‡9 1‏
919 ‎‡a postmenopausalwomenwithahistoryofirregularmensesandelevatedandrogenmeasurementsathighriskforworseningcardiovasculareventfreesurvivalresultsfromthenationalinstitutesofhealthnationalheartlungandbloodinstitutespons‏ ‎‡A Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute spons‏ ‎‡9 1‏
919 ‎‡a prematureatherosclerosisinpremenopausalwomendoescytokinebalanceplayarole‏ ‎‡A Premature atherosclerosis in premenopausal women: Does cytokine balance play a role?‏ ‎‡9 1‏
919 ‎‡a prognosisinwomenwithmyocardialischemiaintheabsenceofobstructivecoronarydiseaseresultsfromthenationalinstitutesofhealthnationalheartlungandbloodinstitutesponsoredwomensischemiasyndromeevaluationwise‏ ‎‡A Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE).‏ ‎‡9 1‏
919 ‎‡a prognosticvalueofglobalmrmyocardialperfusionimaginginwomenwithsuspectedmyocardialischemiaandnoobstructivecoronarydiseaseresultsfromthenhlbisponsoredwisewomensischemiasyndromeevaluationstudy‏ ‎‡A Prognostic value of global MR myocardial perfusion imaging in women with suspected myocardial ischemia and no obstructive coronary disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study‏ ‎‡9 1‏
919 ‎‡a pulsepressureandadverseoutcomesinwomenareportfromthewomensischemiasyndromeevaluationwise‏ ‎‡A Pulse pressure and adverse outcomes in women: a report from the Women's Ischemia Syndrome Evaluation (WISE)‏ ‎‡9 1‏
919 ‎‡a relationsbetweenendogenousandrogensandestrogensinpostmenopausalwomenwithsuspectedischemicheartdisease‏ ‎‡A Relations between endogenous androgens and estrogens in postmenopausal women with suspected ischemic heart disease‏ ‎‡9 1‏
919 ‎‡a relationshipsbetweencardiovasculardiseaseriskfactorsanddepressivesymptomsaspredictorsofcardiovasculardiseaseeventsinwomen‏ ‎‡A Relationships between cardiovascular disease risk factors and depressive symptoms as predictors of cardiovascular disease events in women‏ ‎‡9 1‏
919 ‎‡a renalfunctionandcoronarymicrovasculardysfunctioninwomenwithsymptomssignsofischemia‏ ‎‡A Renal function and coronary microvascular dysfunction in women with symptoms/signs of ischemia‏ ‎‡9 1‏
919 ‎‡a reproductivehormoneexposuretimingandischemicheartdiseasecomplicatedanswerstoasimplequestion‏ ‎‡A Reproductive hormone exposure timing and ischemic heart disease: Complicated answers to a simple question‏ ‎‡9 1‏
919 ‎‡a safetyofcoronaryreactivitytestinginwomenwithnoobstructivecoronaryarterydiseaseresultsfromthenhlbisponsoredwise‏ ‎‡A Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE‏ ‎‡9 1‏
919 ‎‡a safetyofcoronaryreactivitytestinginwomenwithnoobstructivecoronaryarterydiseaseresultsfromthenhlbisponsoredwisewomensischemiasyndromeevaluationstudy‏ ‎‡A Safety of coronary reactivity testing in women with no obstructive coronary artery disease: results from the NHLBI-sponsored WISE (Women's Ischemia Syndrome Evaluation) study‏ ‎‡9 1‏
919 ‎‡a selfratedversusobjectivehealthindicatorsaspredictorsofmajorcardiovasculareventsthenhlbisponsoredwomensischemiasyndromeevaluation‏ ‎‡A Self-rated versus objective health indicators as predictors of major cardiovascular events: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation.‏ ‎‡9 1‏
919 ‎‡a sensitivityandspecificityofcmrifordiagnosisofmicrovascularcoronarydysfunctioninwomenwithsignsandsymptomsofischemiaandnoobstructivecoronaryarterydiseaseresultsfromthenhlbisponsoredwomensischemiasyndromeevaluation‏ ‎‡A SENSITIVITY AND SPECIFICITY OF CMRI FOR DIAGNOSIS OF MICROVASCULAR CORONARY DYSFUNCTION IN WOMEN WITH SIGNS AND SYMPTOMS OF ISCHEMIA AND NO OBSTRUCTIVE CORONARY ARTERY DISEASE: RESULTS FROM THE NHLBI-SPONSORED WOMEN'S ISCHEMIA SYNDROME EVALUATION‏ ‎‡9 1‏
919 ‎‡a sensitivityandspecificityofcmrifordiagnosisofmicrovascularcoronarydysfunctioninwomenwithsignsandsymptomsofischemiaandnoobstructivecoronaryarterydiseaseresultsfromthenhlbisponsoredwomensischemiasyndromeevaluationwi‏ ‎‡A SENSITIVITY AND SPECIFICITY OF CMRI FOR DIAGNOSIS OF MICROVASCULAR CORONARY DYSFUNCTION IN WOMEN WITH SIGNS AND SYMPTOMS OF ISCHEMIA AND NO OBSTRUCTIVE CORONARY ARTERY DISEASE: RESULTS FROM THE NHLBI-SPONSORED WOMEN'S ISCHEMIA SYNDROME EVALUATION (WI‏ ‎‡9 1‏
919 ‎‡a economicburdenofanginainwomenwithsuspectedischemicheartdiseaseresultsfromthenationalinstitutesofhealthnationalheartlungandbloodinstitutesponsoredwomensischemiasyndromeevaluation‏ ‎‡A The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation‏ ‎‡9 1‏
919 ‎‡a relationshipbetweenphysicalactivityandlipoproteinsubclassesinpostmenopausalwomen‏ ‎‡A The relationship between physical activity and lipoprotein subclasses in postmenopausal women‏ ‎‡9 1‏
919 ‎‡a timiframecountandadverseeventsinwomenwithnoobstructivecoronarydiseaseapilotstudyfromthenhlbisponsoredwomensischemiasyndromeevaluation‏ ‎‡A TIMI frame count and adverse events in women with no obstructive coronary disease: a pilot study from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation‏ ‎‡9 1‏
919 ‎‡a timiframecountandadverseeventsinwomenwithnoobstructivecoronarydiseaseapilotstudyfromthenhlbisponsoredwomensischemiasyndromeevaluationwise‏ ‎‡A TIMI frame count and adverse events in women with no obstructive coronary disease: a pilot study from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE)‏ ‎‡9 1‏
919 ‎‡a timingofhormonetherapytypeofmenopauseandcoronarydiseaseinwomendatafromthenationalheartlungandbloodinstitutesponsoredwomensischemiasyndromeevaluation‏ ‎‡A Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation.‏ ‎‡9 1‏
919 ‎‡a bioinformaticsassessmentschemabiastoimprovemyocardialperfusionimagediagnosticandprognosticvaluethenhlbisponsoredwomensischemiasyndromeevaluationwisestudy‏ ‎‡A Bio-informatics assessment schema (BIAS) to improve myocardial perfusion image diagnostic and prognostic value: the NHLBI-sponsored women's ischemia syndrome evaluation (WISE) study.‏ ‎‡9 1‏
919 ‎‡a bioinformaticsassessmentschema‏ ‎‡A Bio-informatics assessment schema‏ ‎‡9 1‏
946 ‎‡a a‏ ‎‡9 1‏
996 ‎‡2 RERO|A025763290‏
996 ‎‡2 LC|no2005022984‏
996 ‎‡2 LC|n 83046950‏
996 ‎‡2 LC|n 82272030‏
996 ‎‡2 ISNI|0000000043435208‏
996 ‎‡2 ISNI|0000000031482429‏
996 ‎‡2 LC|no2017138391‏
996 ‎‡2 W2Z|90896571‏
996 ‎‡2 CAOONL|ncf10092809‏
996 ‎‡2 LC|n 79030695‏
996 ‎‡2 SUDOC|158366344‏
996 ‎‡2 DBC|87097969902723‏
996 ‎‡2 CAOONL|ncf11438303‏
996 ‎‡2 NUKAT|n 2019014283‏
996 ‎‡2 CAOONL|ncf11352866‏
996 ‎‡2 NLA|000035344002‏
996 ‎‡2 LC|no2017007793‏
996 ‎‡2 NLA|000035527404‏
996 ‎‡2 CAOONL|ncf11474247‏
996 ‎‡2 LC|n 86800329‏
996 ‎‡2 ISNI|0000000044535462‏
996 ‎‡2 LC|no2006082701‏
996 ‎‡2 LC|no 99057741‏
996 ‎‡2 ISNI|0000000038729383‏
996 ‎‡2 LC|n 80082978‏
996 ‎‡2 ISNI|0000000038591302‏
996 ‎‡2 ISNI|0000000081137113‏
996 ‎‡2 ISNI|0000000066573224‏
996 ‎‡2 ISNI|0000000083394893‏
996 ‎‡2 NLA|000035249604‏
996 ‎‡2 BIBSYS|90896571‏
996 ‎‡2 DNB|130460737‏
996 ‎‡2 ISNI|0000000053415438‏
996 ‎‡2 LC|n 94114561‏
996 ‎‡2 LC|no2018152833‏
996 ‎‡2 ISNI|0000000383928017‏
996 ‎‡2 ISNI|0000000399231900‏
996 ‎‡2 SUDOC|128527668‏
996 ‎‡2 NLA|000035250043‏
996 ‎‡2 ISNI|0000000042760420‏
996 ‎‡2 LC|n 86079545‏
996 ‎‡2 NKC|jn20010601190‏
996 ‎‡2 LC|n 79094446‏
996 ‎‡2 SUDOC|161538843‏
996 ‎‡2 LC|n 2006091130‏
996 ‎‡2 ISNI|0000000053763125‏
996 ‎‡2 NTA|244151814‏
996 ‎‡2 NLA|000035249469‏
996 ‎‡2 LC|no 95026299‏
996 ‎‡2 NTA|180892002‏
996 ‎‡2 SUDOC|061142018‏
996 ‎‡2 LC|nb2018002258‏
996 ‎‡2 ISNI|0000000110379542‏
996 ‎‡2 NKC|xx0250585‏
996 ‎‡2 DNB|1146394756‏
996 ‎‡2 ISNI|0000000054063411‏
996 ‎‡2 DNB|1162140534‏
996 ‎‡2 NLA|000035248738‏
996 ‎‡2 SUDOC|07567288X‏
996 ‎‡2 LC|no2017133057‏
996 ‎‡2 LC|n 2024029860‏
996 ‎‡2 NUKAT|n 02063484‏
996 ‎‡2 J9U|987007445241205171‏
996 ‎‡2 PLWABN|9811500235605606‏
996 ‎‡2 ISNI|0000000024804565‏
996 ‎‡2 LC|n 82100722‏
996 ‎‡2 SUDOC|267881185‏
996 ‎‡2 N6I|vtls000083753‏
996 ‎‡2 SUDOC|158538404‏
996 ‎‡2 NTA|074575309‏
996 ‎‡2 DNB|1313834777‏
996 ‎‡2 ISNI|0000000384855673‏
996 ‎‡2 NII|DA01592663‏
996 ‎‡2 ISNI|0000000026161938‏
996 ‎‡2 NUKAT|n 2013006934‏
996 ‎‡2 NUKAT|n 2013006935‏
996 ‎‡2 ISNI|0000000075711692‏
996 ‎‡2 RERO|A025913822‏
996 ‎‡2 ISNI|0000000110031239‏
996 ‎‡2 NTA|074141384‏
996 ‎‡2 LC|n 99043991‏
996 ‎‡2 NTA|131416200‏
996 ‎‡2 LC|n 90601781‏
996 ‎‡2 ISNI|0000000002509653‏
996 ‎‡2 ISNI|0000000059783418‏
996 ‎‡2 DNB|122078640‏
996 ‎‡2 NKC|ola2002159291‏
996 ‎‡2 ISNI|0000000067349216‏
996 ‎‡2 ISNI|0000000053406742‏
996 ‎‡2 LC|no2018050283‏
996 ‎‡2 LC|n 79046051‏
996 ‎‡2 LC|n 93013468‏
996 ‎‡2 NTA|094878501‏
996 ‎‡2 BIBSYS|12045064‏
996 ‎‡2 SELIBR|212477‏
996 ‎‡2 LC|no2009148341‏
996 ‎‡2 BNF|12711808‏
996 ‎‡2 BNF|13935455‏
996 ‎‡2 BIBSYS|90806174‏
996 ‎‡2 LC|no2009179091‏
996 ‎‡2 LC|n 85201948‏
996 ‎‡2 ISNI|0000000041716671‏
996 ‎‡2 DBC|87097991128578‏
996 ‎‡2 LC|n 50062974‏
996 ‎‡2 DNB|1313455466‏
996 ‎‡2 BIBSYS|90707237‏
996 ‎‡2 LC|n 2011028596‏
996 ‎‡2 DNB|1013039890‏
996 ‎‡2 LC|no2020131577‏
996 ‎‡2 LC|n 2013052795‏
996 ‎‡2 LC|n 2008075732‏
996 ‎‡2 LC|n 2024016336‏
996 ‎‡2 BNF|13986347‏
996 ‎‡2 BNF|12068338‏
996 ‎‡2 DNB|1117034410‏
996 ‎‡2 NTA|07255584X‏
996 ‎‡2 ISNI|0000000024717680‏
996 ‎‡2 DNB|132131242‏
996 ‎‡2 LC|n 85061602‏
996 ‎‡2 LC|n 81011289‏
996 ‎‡2 LC|no 99007120‏
996 ‎‡2 LC|n 84133469‏
996 ‎‡2 NKC|utb2009515917‏
996 ‎‡2 BIBSYS|9026065‏
996 ‎‡2 NII|DA16302213‏
996 ‎‡2 ISNI|0000000430624893‏
996 ‎‡2 BLBNB|000249676‏
996 ‎‡2 DNB|1061633144‏
996 ‎‡2 SUDOC|077041631‏
996 ‎‡2 LC|n 77019893‏
996 ‎‡2 LC|nb2019020487‏
996 ‎‡2 J9U|987007315320905171‏
996 ‎‡2 ISNI|0000000081658509‏
996 ‎‡2 NKC|jx20100112004‏
996 ‎‡2 NUKAT|n 2018122543‏
996 ‎‡2 BIBSYS|8024833‏
996 ‎‡2 SUDOC|254517811‏
996 ‎‡2 DNB|1071811835‏
996 ‎‡2 LC|n 2012012249‏
996 ‎‡2 LC|n 2003083363‏
996 ‎‡2 LC|n 2007068973‏
996 ‎‡2 LC|n 91054372‏
996 ‎‡2 SUDOC|230806317‏
996 ‎‡2 LC|n 91117233‏
996 ‎‡2 PLWABN|9810543143605606‏
996 ‎‡2 CAOONL|ncf11419834‏
996 ‎‡2 LC|no2012148542‏
996 ‎‡2 DNB|1018471707‏
996 ‎‡2 LC|no2014054461‏
996 ‎‡2 LC|no2018083385‏
996 ‎‡2 DNB|1105418073‏
996 ‎‡2 LC|no2005106956‏
996 ‎‡2 SUDOC|08518781X‏
996 ‎‡2 SUDOC|061629332‏
996 ‎‡2 J9U|987007376432005171‏
996 ‎‡2 LC|no2002007080‏
996 ‎‡2 LC|n 89656487‏
996 ‎‡2 ISNI|0000000072873338‏
996 ‎‡2 DNB|132287803‏
996 ‎‡2 W2Z|14031737‏
996 ‎‡2 BNE|XX1189824‏
996 ‎‡2 BIBSYS|12062912‏
996 ‎‡2 LC|n 87946688‏
996 ‎‡2 CAOONL|ncf10864786‏
996 ‎‡2 ISNI|0000000449665839‏
996 ‎‡2 BNC|981058611915906706‏
996 ‎‡2 LC|no 89000477‏
996 ‎‡2 ISNI|0000000037675491‏
996 ‎‡2 NTA|136173985‏
996 ‎‡2 CAOONL|ncf10408984‏
996 ‎‡2 SUDOC|270805494‏
996 ‎‡2 ISNI|0000000028599730‏
996 ‎‡2 ISNI|0000000116914956‏
996 ‎‡2 LIH|LNB:CC_o__z_;=B,‏
996 ‎‡2 NUKAT|n 2017076237‏
996 ‎‡2 DNB|1113209992‏
996 ‎‡2 LIH|LNB:LTA;=_z_W‏
996 ‎‡2 LC|no2022097741‏
996 ‎‡2 PLWABN|9810683466105606‏
996 ‎‡2 CAOONL|ncf11364965‏
996 ‎‡2 BIBSYS|1615358753029‏
996 ‎‡2 ISNI|0000000038027330‏
996 ‎‡2 SUDOC|085950785‏
996 ‎‡2 ISNI|000000004641586X‏
996 ‎‡2 ISNI|0000000051888506‏
996 ‎‡2 DNB|1022393693‏
996 ‎‡2 LC|no2010053024‏
996 ‎‡2 CAOONL|ncf11309694‏
996 ‎‡2 BNC|981058512921206706‏
996 ‎‡2 NII|DA03597850‏
996 ‎‡2 BIBSYS|97053799‏
996 ‎‡2 PTBNP|1162367‏
996 ‎‡2 ISNI|0000000430498399‏
996 ‎‡2 CAOONL|ncf11737104‏
996 ‎‡2 ISNI|0000000030634793‏
996 ‎‡2 LC|nb 97050003‏
996 ‎‡2 ISNI|000000049613431X‏
996 ‎‡2 SUDOC|089560213‏
996 ‎‡2 LC|no2016082791‏
996 ‎‡2 CAOONL|ncf11301196‏
996 ‎‡2 CAOONL|ncf11301197‏
996 ‎‡2 LC|n 2011063215‏
996 ‎‡2 CAOONL|ncf11301195‏
996 ‎‡2 CAOONL|ncf11301193‏
996 ‎‡2 LC|no 88001369‏
996 ‎‡2 CAOONL|ncf11162676‏
996 ‎‡2 KRNLK|KAC200504824‏
996 ‎‡2 CAOONL|ncf11165809‏
996 ‎‡2 LC|nb 98001741‏
996 ‎‡2 CAOONL|ncf10184370‏
996 ‎‡2 BNF|13895670‏
996 ‎‡2 BNF|13895671‏
996 ‎‡2 BIBSYS|90154305‏
996 ‎‡2 ISNI|0000000075278905‏
996 ‎‡2 LC|n 85800225‏
996 ‎‡2 LC|no2022128978‏
996 ‎‡2 NDL|001329242‏
996 ‎‡2 CAOONL|ncf11320802‏
996 ‎‡2 LC|n 88117081‏
996 ‎‡2 LC|no2018097593‏
996 ‎‡2 LC|n 88647611‏
996 ‎‡2 LC|no2009086324‏
996 ‎‡2 ISNI|0000000071410729‏
996 ‎‡2 ISNI|0000000066303232‏
996 ‎‡2 DBC|87097991128632‏
996 ‎‡2 ISNI|0000000118981175‏
996 ‎‡2 NLA|000035590829‏
996 ‎‡2 LC|n 90609242‏
996 ‎‡2 NYNYRILM|12948‏
996 ‎‡2 SKMASNL|vtls010973124‏
996 ‎‡2 NYNYRILM|12943‏
996 ‎‡2 RERO|A003427987‏
996 ‎‡2 CAOONL|ncf11556373‏
996 ‎‡2 DNB|1081518499‏
996 ‎‡2 PTBNP|1674929‏
996 ‎‡2 LC|n 2017183070‏
996 ‎‡2 DNB|130846295‏
996 ‎‡2 BNF|13482707‏
996 ‎‡2 NSK|000339171‏
996 ‎‡2 ISNI|0000000033386641‏
996 ‎‡2 J9U|987007433413805171‏
996 ‎‡2 ISNI|0000000073929444‏
996 ‎‡2 LC|nb2009022506‏
996 ‎‡2 LC|no2018153456‏
996 ‎‡2 NII|DA17643661‏
996 ‎‡2 LC|nb2010018492‏
996 ‎‡2 DNB|121290751‏
996 ‎‡2 LC|no2011052933‏
996 ‎‡2 NLA|000035249661‏
996 ‎‡2 PLWABN|9810539906605606‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏